缺血性脑血管疾病已成为威胁人类健康的疾病之一，脑缺血再灌注的发病机制复杂，脑缺血再灌注损伤是造成患者预后不良的主要原因。黄芪甲苷可通过减轻神经组织炎性损伤、减轻氧化应激反应、抑制神经组织细胞凋亡、调节钙稳态、促进神经组织修复、双向调节NK细胞功能、保护血脑屏障、阻止异常磷酸化Tau的积累、减轻脑水肿防治脑缺血再灌注损伤。总结了黄芪甲苷防治脑缺血再灌注损伤的药理作用研究进展，为脑缺血再灌注损伤的治疗提供选择和参考。

Ischemic cerebrovascular disease has become one of the diseases that threaten human health. The pathogenesis of cerebral ischemia-reperfusion is complex, and cerebral ischemia-reperfusion injury is the main cause of poor prognosis in patients. Astragaloside IV can prevent and treat cerebral ischemia-reperfusion injury by reducing inflammatory damage to nerve tissue, alleviating oxidative stress response, inhibiting apoptosis of neural tissue cells, regulating calcium homeostasis, promoting neural tissue repair, bidirectionally regulating NK cell function, protecting the blood-brain barrier, preventing abnormal phosphorylation of Tau accumulation, reducing brain edema. This article summarizes the pharmacological research progress of astragaloside IV in preventing and treating cerebral ischemia-reperfusion injury, providing options and references for treatment of cerebral ischemia-reperfusion injury.

R285.5

神经与肿瘤药物研发全国重点实验室开放课题（SKLSIM-F-202487）